OR WAIT null SECS
released a new offering for the Life Sciences market. The AdverseEvent Case Processing solution revolutionizes how organizations collect, manage, and analyze adverse events both during and after clinical trials, thereby shortening the timeline for conducting successful clinical trials and improving the post-approval management of safety information.
All clinical trials and marketed products have the potential to produce adverse events ranging from minor to serious in nature, even when available to the general public. Adverse events categorized as "serious," or something that could result in initial or prolonged hospitalization, death, etc., must be reported to regulatory authorities immediately. In a highly competitive industry where patent expirations and rising drug development costs are pressuring bottom lines, life sciences companies need better operational efficiency to adapt to changing regulations and reduce costs. The Adverse Event Case Processing solution improves critical stages of pharmacovigilance operations. New automation and operational efficiencies that leverage built-in business process management capabilities, include:
This new solution deploys rapidly by using advanced technologies to quickly leverage existing adverse event processing rules and requirements and can produce dynamic specialized documentation to help ensure compliance in a validated environment.